While Adaptive Biotechnologies Corp has overperformed by 1.53%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADPT rose by 165.72%, with highs and lows ranging from $20.76 to $5.80, whereas the simple moving average jumped by 34.11% in the last 200 days.
On December 02, 2025, Morgan Stanley started tracking Adaptive Biotechnologies Corp (NASDAQ: ADPT) recommending Equal-Weight. A report published by Guggenheim on September 30, 2025, Initiated its previous ‘Buy’ rating for ADPT. Craig Hallum also rated ADPT shares as ‘Buy’, setting a target price of $15 on the company’s shares in an initiating report dated June 18, 2025. JP Morgan initiated its ‘Overweight’ rating for ADPT, as published in its report on July 05, 2023. Scotiabank’s report from January 05, 2023 suggests a price prediction of $15 for ADPT shares, giving the stock a ‘Sector Outperform’ rating. Piper Sandler also rated the stock as ‘Overweight’.
Analysis of Adaptive Biotechnologies Corp (ADPT)
Further, the quarter-over-quarter increase in sales is 102.38%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Adaptive Biotechnologies Corp’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -37.18% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.26, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and ADPT is recording an average volume of 2.28M. On a monthly basis, the volatility of the stock is set at 7.22%, whereas on a weekly basis, it is put at 5.54%, with a gain of 7.20% over the past seven days. Furthermore, long-term investors anticipate a median target price of $19.86, showing growth from the present price of $15.93, which can serve as yet another indication of whether ADPT is worth investing in or should be passed over.
How Do You Analyze Adaptive Biotechnologies Corp Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 3.87%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 93.87% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
